GlassScriptPhysician profile
Marybeth Rivard
NPI 1174507487
$41,098.96
in general payments reported to CMS, 2019-2025
13 companies · $647 in 2025
The $647 reported for 2025 was more than what 77% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.47 · 2022: $676 · 2023: $1,148 · 2024: $39K · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Travel and Lodging: $9,977 · Food and Beverage: $4,370 · Consulting Fee: $3,720 · Education: $10.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,276.00 |
| Travel and Lodging | $9,977.11 |
| Food and Beverage | $4,369.70 |
| Consulting Fee | $3,720.00 |
| Education | $10.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $38,485.14 | 2022-2025 | Descovy, Biktarvy |
| Viiv Healthcare Company | $1,440.00 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Janssen Biotech, INC. | $267.93 | 2021-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $209.85 | 2022-2025 | Delstrigo, Pifeltro, Dificid |
| Lilly USA, LLC | $181.07 | 2022-2023 | Mounjaro |
| Napo Pharmaceuticals INC | $171.07 | 2023-2025 | Mytesi |
| Abbvie INC. | $117.84 | 2023-2025 | |
| Novo Nordisk INC | $66.35 | 2023-2024 | Ozempic |
| Antares Pharma, INC. | $43.85 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Theratechnologies INC. | $40.16 | 2024-2025 | Egrifta, Trogarzo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.99 | 2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $25.67 | 2025 | Rexulti |
| Exact Sciences Corporation | $22.04 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marybeth Rivard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.